Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who have a diagnosis of Giant Cell Arteritis (GCA)~* Patients who have a diagnosis of GCA of = 4 weeks' duration~* Patients who are receiving = 40 mg/day of prednisone/prednisolone Exclusion Criteria:~* Patients must not have a prior diagnosis of GCA \> 4 weeks~* Patients must not have failed to respond to glucocorticosteroid therapy within 5 days of initiation of therapy.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).